Regulations

FDA Issues Warning Letter to Patcos Cosmetics

The citation summarizes violations of CGMP regulations at the private label company.

The United States Food and Drug Administration (FDA) issues a warning letter to Patcos Cosmetics of India for violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The company specializes in private label oral care and aerosol products. The FDA conducted an unannounced inspection of the drug manufacturing facility, Patcos Cosmetics Pvt. Ltd., FEI 3009250196, at Survey No. 659, A Kevdi Falia Road, Daman, Dadra and Nagar Haveli and Daman, India, from...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters